UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934

 
Date of Report (Date of earliest event reported): June 15, 2005
 

   
 NovaMed, Inc.
    
   
 (Exact Name of Registrant as Specified in Charter)
    
         
 Delaware
  
  0-26625
  
 36-4116193
 (State or Other Jurisdiction 
  
 (Commission
  
 (IRS Employer
 of incorporation)
  
  File Number)
  
 Identification No.)
         
     
 980 North Michigan Avenue, Suite 1620, Chicago, Illinois
  
  60611
 (Address of Principal Executive Offices) 
      
 (Zip Code)
         
  Registrant’s telephone number, including area code (312) 664-4100


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 
 
 

Section 1 - Registrant’s Business and Operations

Item 1.01 Entry into a Material Definitive Agreement

On April 25, 2005, the Board of Directors of NovaMed, Inc. (the “Company”) approved the Company’s 2005 Stock Incentive Plan (“Plan”) pursuant to which 1,400,000 shares of the Company’s common stock were authorized to be issued on the terms set forth in the Plan. The Board of Directors approved the Plan subject to the Company’s stockholders approving it at the Company’s annual meeting of stockholders on June 15, 2005. At the June 15th stockholders’ meeting in which a quorum was present in person or by proxy, the Company’s stockholders approved the Plan, with 10,110,250 shares voting in favor of the Plan, 2,981,239 shares voting against the Plan, and 130,830 shares abstaining.


 
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
  NovaMed, Inc.
 
 		  
 		  
 
Dated: June 21, 2005 By:   /s/ Scott T. Macomber  
 
Scott T. Macomber
  Executive Vice President and Chief Financial Officer